Chief Science Officer · Traws Pharma, Inc. (TRAW)

Charles Pauza

FY2025 is the first fiscal year CompBrief holds for Charles Pauza as a named executive officer of Traws Pharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,014,040

Salary $500,000Stock awards $43,037Bonus $180,000

2nd of 4 named executive officers at Traws Pharma by FY2025 total.

4 named officers on file for Traws Pharma, FY2025

Charles Pauza’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Traws Pharma’s whole pay program stands against its peers

  • Traws Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TRAW→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 29, 2026 (DEF 14A).

Free

Get Charles Pauza’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Pauza compensation by year

Traws Pharma Summary Compensation Table · the one fiscal year held
In US dollars, as Traws Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$500,000
Bonus$180,000
Stock awards$43,037
Option awards$269,696
Non-equity incentive$0
Pension and deferred compensation$0
All other$21,307
Total$1,014,040

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Traws Pharma, Inc. DEF 14A filed May 29, 2026, accession 0001104659-26-067945, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Traws Pharma, Inc. filed document, accession 0001104659-26-067945. Every figure is read from that document and cited to the page and table it appears in. Filed May 29, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,471$20,872—
RSU2,925$3,305—
Option1,054—$2.33
Option32,406—$3.01
Option72,832—$2.33

Per the Outstanding Equity Awards at Fiscal Year-End table in Traws Pharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Traws Pharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
D. Iain DukesChief Executive Officer$1,401,924
Charles Pauza · this pageChief Science Officer$1,014,040
Nikolay SavchukChief Operating Officer$734,810
Werner CautreelsFormer Chief Executive Officer$353,897

The full Traws Pharma compensation record

free company brief

This page is one person within Traws Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Traws Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Pauza's compensation dossier · One-time report. No refunds.